12.24

3.12% 0.37

Pre-market: 12.55 0.31 +2.53%

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $12.24, with a volume of 351.57K. It is up +3.12% in the last 24 hours and up +8.32% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$11.87

Open:

$11.77

24h Volume:

351.57K

Relative Volume:

0.84

Market Cap:

$241.34M

Revenue:

$244.06M

Net Income/Loss:

$87.01M

P/E Ratio:

6.7205

EPS:

1.8213

Net Cash Flow:

$105.95M

1W Performance:

+10.87%

1M Performance:

+8.32%

6M Performance:

-21.79%

1Y Performance:

+22.65%

1-Day Range:

$11.50

$12.24

1-Week Range:

$11.08

$12.24

52-Week Range:

$9.12

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1110)

Industry

Biotechnology (624)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

Twitter

Next Earnings Date

2026-02-27

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	12.24	241.34M	244.06M	87.01M	105.95M	1.8213
VRTX Vertex Pharmaceuticals Inc	431.86	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	760.27	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	765.43	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	319.52	42.63B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.03	35.19B	606.42M	-1.28B	-997.58M	-6.403

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

03:02 AM

Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN

03:02 AM

Apr 07, 2026

BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics - Stock Titan

Apr 07, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts - MarketBeat

Apr 07, 2026

Apr 06, 2026

Keros Therapeutics (KROS) CEO exercises options for 55,000 shares - Stock Titan

Apr 06, 2026

JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS - MarketBeat

Apr 06, 2026